Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers
Anshari Saifuddin Hasibuan,
Sukamto Koesnoe,
Alvina Widhani,
Muhadi Muhadi,
Hamzah Shatri,
Eka Ginanjar,
Evy Yunihastuti,
Pradana Soewondo,
Sally Aman Nasution,
Samsuridjal Djauzi,
Lies Dina Liastuti,
Trimartani Koento,
Sumariyono Sumariyono,
Astri Mulyantini
Affiliations
Anshari Saifuddin Hasibuan
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Sukamto Koesnoe
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Alvina Widhani
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Muhadi Muhadi
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Hamzah Shatri
Division of Psychosomatic and Palliative Care, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Eka Ginanjar
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Evy Yunihastuti
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Pradana Soewondo
Division of Endocrine System, Metabolism and Diabetes, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Sally Aman Nasution
Indonesian Society of Internal Medicine, Jakarta 10430, Indonesia
Samsuridjal Djauzi
Adult Immunization Task Force, Indonesian Society of Internal Medicine, Jakarta 10430, Indonesia
Lies Dina Liastuti
Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Trimartani Koento
Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Sumariyono Sumariyono
Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
Astri Mulyantini
Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia
The COVID-19 pandemic has caused significant morbidity and mortality worldwide, especially among health-care workers. One of the most important preventive measures is vaccination. This study examined factors associated with the incidence rate of SARS-CoV-2 infection after mRNA-1273 booster vaccination (preceded by the CoronaVac primary vaccination) and the antibody profile of health-care workers at one of the tertiary hospitals in Indonesia. This was a combined retrospective cohort and cross-sectional study. Three hundred health-care workers who were given the mRNA-1273 booster vaccine a minimum of 5 months prior to this study were randomly selected. Participants were then interviewed about their history of COVID-19 vaccination, history of SARS-CoV-2 infection, and comorbidities. Blood samples were taken to assess IgG sRBD antibody levels. The median antibody level was found to be 659 BAU/mL (min 37 BAU/mL, max 5680 BAU/mL, QIR 822 BAU/mL) after the booster, and this was not related to age, sex, comorbidities, or adverse events following immunization (AEFI) after the booster. SARS-CoV-2 infection after the booster was correlated with higher antibody levels. In sum, 56 participants (18.6%) experienced SARS-CoV-2 infection after the mRNA-1273 booster vaccination within 5 months. Incidence per person per month was 3.2%. Age, sex, diabetes mellitus type 2, hypertension, obesity, and post-booster AEFI were not related to COVID-19 incidence after the booster. History of SARS-CoV-2 infection before the booster vaccination was significantly associated with a reduced risk of SARS-CoV-2 infection after booster vaccination, with a relative risk (RR) of 0.21 (95% CI 0.09–0.45, p < 0.001).
